𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China

✍ Scribed by Li Liu; Hong Zhou Lu; Mireille Henry; Catherine Tamalet

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
106 KB
Volume
79
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Few data are available for genotypic patterns within human immunodeficiency virus‐1 (HIV‐1) reverse transcriptase (RT) in drug‐naive patients and RT inhibitor (RTI) treated patients in China. This study aimed at characterizing the polymorphism of RT HIV‐1 in the absence of drug treatment and to identify known and unknown mutations emerging under RTI selective pressure. The HIV‐1 RT gene from 21 drug‐naive patients and 81 RTI treated patients from three provinces in China was analyzed. Most patients (>80%) received a triple regimen including stavudine (d4T) plus didanosine (ddI) and nevirapine (NVP), or d4T plus lamivudine (3TC) and efavirenz (EFV), or zidovudine (AZT) +ddI + NVP. In untreated patients, four highly polymorphic positions were found (122, 200, 207, and 211). In treated patients, two patterns of resistance associated mutations (RAMs) were observed: (1) K65R (9.8%), L74V (7.4%), M184V (7.4%), Q151M (5%), and thymidine analogue mutations (TAMs) (9.3%) including T215Y (5.5%), in patients who underwent ddI + d4T + NVP. (2) T215Y (23%), M184V (20%), and TAMs (15.4%) in patients receiving d4T + 3TC + EFV. In all cases, a high prevalence of non‐nucleoside RTIs (NNRTI) RAMs (41.9%) was found. Four RTI suspected new RAMs were described at position 142, 221, 224, and 228. An association between H221Y and L228H/R with Y181C was noted. These data highlight the predominant spread of NNRTI RAM in China, depict the specific genotypic pattern of RTI selected mutations in China, and suggest the association of newly described mutations with RTI therapy. J. Med. Virol. 79:1593–1599, 2007. © Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Polymorphism and drug-selected mutations
Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France
✍ Philippe Colson; Mireille Henry; Natacha Tivoli; Hervé Gallais; Jean-Albert Gast 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB

Few data are available about the susceptibility and the genotypic resistance pattern of human immunodeficiency virus type 2 (HIV-2) to nucleoside reverse transcriptase inhibitors (NRTIs). The HIV-2 reverse transcriptase (RT) gene from 25 HIV-2-infected patients followed-up in Marseilles and the surr

HIV-1 reverse transcriptase drug-resista
HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon
✍ Sherri T. Burda; Ragupathy Viswanath; Jiangqin Zhao; Thompson Kinge; Christopher 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

## Abstract The most common first‐line, highly active anti‐retroviral therapy (HAART) received by individuals infected with HIV‐1 in Cameroon is the combination therapy Triomune, comprised of two nucleoside reverse transcriptase inhibitors (NRTI) and one non‐NRTI (NNRTI). To examine the efficacy of

Relationship between mutations in HIV-1
Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients
✍ Bénédicte Roquebert; Marc Wirden; Anne Simon; Jérome Deval; Christine Katlama; V 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

## Abstract Recent studies have highlighted the need of investigating the in vivo role of ribonuclease H (RNase H) in nucleoside reverse transcriptase inhibitors (NRTIs) resistance. The prevalence of RNase H mutations in naive and in NRTI pre‐treated patients in regimen failure were compared and so

High frequency of selection of K65R and
High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen
✍ Diane Descamps; Florence Damond; Sophie Matheron; Gilles Collin; Pauline Campa; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 1 views

## Abstract The objective of the study was to determine retrospectively which substitutions in the reverse transcriptase (RT) gene are selected in vivo during nucleoside RT inhibitors (NRTI) containing regimen in HIV‐2 infected subjects. Thirty‐four HIV‐2 patients having received NRTI‐containing re

An in-house HIV genotyping assay for the
An in-house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV-1
✍ Chun Kiat Lee; Hong Kai Lee; Tze Ping Loh; Sunil Kumar Sethi; Evelyn Siew-Chuan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract Genotyping for HIV drug resistance is costly and beyond the means for many Southeast Asian patients, who are self‐funded. This prompted the development of a more cost‐effective, in‐house assay for an ethnically diverse, Southeast Asian population at the National University Hospital in S

Human immunodeficiency virus type 1 prot
Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil
✍ Rafael Brandão Varella; Selma Baía Ferreira; Márcia Braga de Castro; Mariano Gus 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB

## Abstract The presence of genetic mutations in HIV‐1‐positive untreated individuals and its contribution to treatment failure, either in an individual or on a population basis, remains an important concern. The goal was to analyze and compare HIV‐1 reverse transcriptase (RT) and protease (PR) gen